Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy mayjeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy mayjeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
Targeted cancer therapy mayjeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
A mutant protein called Siglec-XII may promote carcinoma progression in humans, but inactivation of its gene seems to avoid the problem, according to a study.
From his student days in veterinary medicine in Ethiopia to running a lab on metastasis at MD Anderson Cancer Center, Debeb has a passion for understanding how living things work.
Researchers turned white blood cells called neutrophils into drug-smuggling “neutrobots,” which penetrated the blood-brain barrier to treat brain cancer in mice.
Death rates among blood cancer patients who contract COVID-19 are higher than for those with other cancers, pointing to impaired immunity that makes it hard to overcome the virus.